Bioeq AG
Peter Durrer is an experienced professional in the field of quality assurance and regulatory affairs, with a strong background in the pharmaceutical and biotech industry. Peter has held various leadership roles in companies such as Bioeq AG, Thermo Fisher Scientific, SAKK Swiss Group for Clinical Cancer Research, Crucell, and Berna Biotech Ltd. Peter is known for their expertise in quality control operations and compliance with regulatory standards. Peter also has a PhD in natural sciences with a specialization in Biochemistry from ETH Zürich.
This person is not in any teams
This person is not in any offices
Bioeq AG
Bioeq AG is a Swiss biopharmaceutical joint venture backed by the leading biosimilar developers Polpharma Biologics Group and Formycon AG and is based in Zug. We license, develop and commercialise a biosimilar, which is a successor product of Lucentis® (ranibizumab), a successful branded biopharmaceutical. We are a young and dynamic company, supported by an international network of experts. Bioeq AG out-licenses its products to established international pharmaceutical companies who ensure local distribution in each territory.